Vaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) — Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq:VAXX), a U.S. company pioneering the development of a new class of medicines, today announced issued a letter to shareholders from its Co-founder and Executive Chairman, Lou Reese and Chief Executive Officer, Mei Mei Hu.
Related news for (VAXX)
- Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
- Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates